Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients
- First Online:
- 108 Downloads
The presence of disseminated tumor cells in the bone marrow of breast cancer patients has proven to be an independent prognostic factor. The aim of this study was to investigate the status of tumor cell dissemination after primary systemic therapy in relation to therapy response.
Bone marrow aspirates were obtained from 120 patients after completion of primary systemic therapy. Disseminated tumor cells were detected by immunocytochemistry using the APAAP method. Bone marrow status was correlated with clinicopathological factors as well as tumor response to primary systemic therapy.
Sixty out of 120 patients had disseminated tumor cells in their bone marrow aspirates (50%). Response rates were 18% for pathologic complete remission, 52% for partial remission, 28% for no change and 3% for progression. Despite complete remission, 36% of these patients were bone marrow positive. In the partial remission group, the positivity rate was 48%. About 61% of patients with stable disease had disseminated tumor cells in their bone marrow. A trend to higher positivity rates was observed in the poor responder group compared to responders (61% vs. 38%, P = 0.1).
Primary systemic therapy does not completely eradicate disseminated tumor cells in the bone marrow of breast cancer patients. The biological role of persistent disseminated tumor cells needs to be further investigated to optimize current and future therapeutic strategies.
KeywordsBreast cancer Primary systemic therapy Disseminated tumor cells Neoadjuvant therapy
- 4.von Minckwitz G, Raab G, Schütte M et al (2003) Dose-dense versus sequential Adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2–3, N0–2, M0): Primary endpoint analysis of the GEPARDUO study. Proc Am Soc Clin Oncol 21:43a, (abstr 168)Google Scholar
- 5.NSABP: The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: Preliminary results of the NSABP Protocol B-27. Breast Cancer Res Treat 69:210, (abstr 5) 2001 (updated with personal communication 2002, 2003)Google Scholar
- 7.Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493PubMedGoogle Scholar
- 14.Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005 Aug 25, 353(8):793–802Google Scholar
- 18.Scholl SM, Beuzeboc P, Harris AL, Pierga JY, Asselain B, Palangie T, Dorval T, Jouve M, Dieras V, Pouillart P (1998) Is primary chemotherapy useful for all patients with primary invasive breast cancer ? Recent Res Cancer Res 152:217–226Google Scholar
- 21.Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525–533PubMedCrossRefGoogle Scholar
- 23.Diel IJ, Kaufmann M, Solomayer E-F, Wallwiener D, Gollan C,Goerner R, Kaul S, Costa SD, von Minckwitz G, Holle R, Bastert R (1997) Prognostische Bedeutung des Tumorzellnachweises im Knochenmark im Vergleich zum Nodalstatus beim primären Mammakarzinom. Geburtsh u Frauenheilk 57:333–341CrossRefGoogle Scholar
- 24.Naume B, Wiedswang G, Borgen E, Kvalheim G, Karesen R, Qvist H, Janbu J, Harbitz T, Nesland JM (2004) The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res 10(9):3091–3097PubMedCrossRefGoogle Scholar
- 25.Becker S, Becker-Pergola G, Wallwiener D, Solomayer EF, Fehm T (2005) Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy.Breast Cancer Res Treat 2005 Dec 1:1–6Google Scholar
- 26.Thurm H, Ebel S, Kentenich C, Hemsen A, Riethdorf S, Coith C, Wallwiener D, Braun S, Oberhoff C, Janicke F, Pantel K (2003) Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res 9(7):2598–2604PubMedGoogle Scholar
- 27.Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K (2000) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol Jan 18(1):80–86Google Scholar
- 28.Slade MJ, Singh A, Smith BM, Tripuraneni G, Hall E, Peckitt C, Fox S, Graham H, Luchtenborg M, Sinnett HD, Cross NC, Coombes RC (2005) Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years.Int J Cancer 2005 Mar 10, 114(1):94–100Google Scholar
- 29.Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K (2005) The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence.Cancer. 2005 Mar 1, 103(5):884–891Google Scholar
- 30.Roggel F, Hocke S, Lindemann K, Sinz S, Welk A, Bosl M, Pabst M, Nusser N, Braun S, Schmitt M, Harbeck N (2003) Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance. Recent Res Cancer Res 162:89–100Google Scholar
- 32.Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJF, Kaufmann M, Diebold J, Arnholdt H, Müller P, Bischoff J, Harich D, Schlimok G, Rietmüller G, Eils R, Klein CA (2003) From latent disseminated cells to overt metastases: genetic analyis of systemic breast cancer progression. PNAS 100:7737–7742PubMedCrossRefGoogle Scholar